Key Publications

CN EN

Home
About Us
- Company Profile
- Culture
- Core Team
- History
- Honor
Innovation
News
Career
Contact Us

Innovation

Dedicated to R&D of Medicines for
Respiratory and Pediatric Diseases

Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection

Zhao S, et al. The New England Journal of Medicine. September 2024

More→
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency

Zhang H, et al. Journal of Infection. February 2024

More→
Current state and challenges in respiratory syncytial virus drug discovery and development

Zou G, et al. Antiviral Research. Jan 2024

More→
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein

Dai L, et al. hLife. November 2023

More→
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial

Huang LM, et al. Influenza Other Respi Viruses. July 2023

More→
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Zheng XF, et al. Journal of Medicinal Chemistry. July 2019

More→
Comparison of antiviral resistance across acute and chronic viral infections

Mason S, et al. Antiviral Research. October 2018

More→

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Official account

© 2021-2024 Ark Biopharmaceutical 沪ICP备2021015938号-1 沪公网安备 31011502017941

        
HOME

TEL

TOP